Philippe De Wals1. 1. Department of Social and Preventive Medicine, Laval University and National Institute of Public Health, Quebec City, Quebec.
Abstract
OBJECTIVE: To evaluate the benefit and costs of vaccination of university students against invasive meningococcal disease (IMD) in Canada. METHODS: Published studies were reviewed and a simulation model was used. RESULTS: IMD risk seems to be of low magnitude, but consequences can be dramatic. Over a 10-year period, IMD risk reduction would be slightly greater using a monovalent C conjugate vaccine than a quadrivalent polysaccharide vaccine. From a societal perspective, costs per quality-adjusted life-years gained would be between $135,000 and $698,000, according to epidemiological scenarios and with vaccine purchase prices between $35 and $50 per dose. CONCLUSIONS: Economic indices exceed proposed criteria for cost effective public health programs, but from the perspective of students and parents, the cost of vaccination might be worth the benefit.
OBJECTIVE: To evaluate the benefit and costs of vaccination of university students against invasive meningococcal disease (IMD) in Canada. METHODS: Published studies were reviewed and a simulation model was used. RESULTS: IMD risk seems to be of low magnitude, but consequences can be dramatic. Over a 10-year period, IMD risk reduction would be slightly greater using a monovalent C conjugate vaccine than a quadrivalent polysaccharide vaccine. From a societal perspective, costs per quality-adjusted life-years gained would be between $135,000 and $698,000, according to epidemiological scenarios and with vaccine purchase prices between $35 and $50 per dose. CONCLUSIONS: Economic indices exceed proposed criteria for cost effective public health programs, but from the perspective of students and parents, the cost of vaccination might be worth the benefit.
Authors: K M Zangwill; R W Stout; G M Carlone; L Pais; H Harekeh; S Mitchell; W H Wolfe; V Blackwood; B D Plikaytis; J D Wenger Journal: J Infect Dis Date: 1994-04 Impact factor: 5.226
Authors: P B Imrey; L A Jackson; P H Ludwinski; A C England; G A Fella; B C Fox; L B Isdale; M W Reeves; J D Wenger Journal: Am J Epidemiol Date: 1996-03-15 Impact factor: 4.897